

Title (en)  
ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION

Title (de)  
ANTISENSE OLIGONUKLEOTIDE ZUR HEMMUNG DER VEGF-EXPRESSION

Title (fr)  
OLIGONUCLEOTIDES ANTISENS DESTINES A INHIBER L'EXPRESSION DE VEGF

Publication  
**EP 1102842 A2 20010530 (EN)**

Application  
**EP 99938373 A 19990729**

Priority  
• EP 99938373 A 19990729  
• EP 9905432 W 19990729  
• EP 98114854 A 19980807

Abstract (en)  
[origin: EP0978561A1] The present invention relates to an oligonucleotide or a derivative thereof which has a sequence that corresponds to a part of a nucleic acid which encodes VEGF (vascular endothelial growth factor) and which has the ability to inhibit tumor growth in animal tumor models, the invention further relates to the preparation of such oligonucleotide and the use thereof. An oligonucleotide or a derivative thereof which has the sequence SEQ ID NO. 4 or a part thereof, wherein SEQ ID NO. 4 is 3'-GTACCTACAGATAGTCGCGTCGATGACGGTAGG-5' @ , with the first proviso, that not all internucleoside bridges in the oligonucleotide are phosphodiester internucleoside bridges and not all phosphodiester internucleoside bridges are replaced by phosphorothioate internucleoside bridges and/or the second proviso, that the oligonucleotide contains no modified nucleosides selected from C5-propynyl uridine, C5-propynyl cytidine, C5-hexynyl uridine, C5-hexynyl cytidine, 6-aza uridine and 6-aza cytidine.

IPC 1-7  
**C12N 15/11**; **A61K 31/70**; **C07H 21/00**

IPC 8 full level  
**A61K 31/70** (2006.01); **A61K 31/7088** (2006.01); **A61K 48/00** (2006.01); **A61P 9/00** (2006.01); **C12N 15/09** (2006.01); **A61P 13/12** (2006.01); **A61P 17/06** (2006.01); **A61P 27/02** (2006.01); **A61P 29/00** (2006.01); **A61P 35/00** (2006.01); **A61P 35/04** (2006.01); **A61P 43/00** (2006.01); **C07H 21/00** (2006.01); **C07H 21/04** (2006.01); **C12N 15/113** (2010.01); **A61K 38/00** (2006.01)

CPC (source: EP KR)  
**A61P 9/00** (2018.01 - EP); **A61P 13/12** (2018.01 - EP); **A61P 17/06** (2018.01 - EP); **A61P 27/02** (2018.01 - EP); **A61P 29/00** (2018.01 - EP); **A61P 35/00** (2018.01 - EP); **A61P 35/04** (2018.01 - EP); **A61P 43/00** (2018.01 - EP); **C12N 15/11** (2013.01 - KR); **C12N 15/1136** (2013.01 - EP); **A61K 38/00** (2013.01 - EP); **C12N 2310/31** (2013.01 - EP); **C12N 2310/315** (2013.01 - EP); **C12N 2310/318** (2013.01 - EP); **C12N 2310/32** (2013.01 - EP); **C12N 2310/321** (2013.01 - EP); **C12N 2310/322** (2013.01 - EP); **C12N 2310/33** (2013.01 - EP); **C12N 2310/346** (2013.01 - EP)

C-Set (source: EP)  
**C12N 2310/321** + **C12N 2310/3521**

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)  
**EP 0978561 A1 20000209**; AU 5289399 A 20000228; CA 2339340 A1 20000217; EP 1102842 A2 20010530; HU P0103290 A2 20011228; JP 2002523335 A 20020730; KR 20010072312 A 20010731; PL 346162 A1 20020128; WO 0008140 A2 20000217; WO 0008140 A3 20000518

DOCDB simple family (application)  
**EP 98114854 A 19980807**; AU 5289399 A 19990729; CA 2339340 A 19990729; EP 9905432 W 19990729; EP 99938373 A 19990729; HU P0103290 A 19990729; JP 2000563767 A 19990729; KR 20017001612 A 20010206; PL 34616299 A 19990729